Muzaffar H. Qazilbash MD

Muzaffar H. Qazilbash, MD, is a Professor in the Department of Stem Cell Transplantation and Cellular Therapy at UT MD Anderson Cancer Center, which he joined in October 2002. He completed his hematology-oncology fellowship at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Qazilbash's clinical and research work has been focused on improving the outcomes of stem cell transplantation and cellular therapy for patients with multiple myeloma and related disorders.

As Director of Myeloma Transplantation and Cellular Therapy in the Department of Stem Cell Transplantation and Cellular Therapy, Dr. Qazilbash leads one of the largest myeloma transplant programs in the country. He has led several clinical trials for myeloma and related disorders, funded by the NIH and various philanthropic organizations. He has served as the Principal Investigator for the idiotype vaccine and cellular therapy studies (2004-0660, 2010- 0710) for myeloma, funded by the National Cancer Institute (SPORE) and the Leukemia Lymphoma Society (SCOR). He also led the PR1 vaccine trial (DM97-325), an NCI-sponsored study (# T98-0017) that received national recognition due to its novel approach and encouraging results.

Dr. Qazilbash has authored or co-authored more than 220 articles in peer-reviewed medical journals and serves in leadership positions at various institutional and extramural committees. He has been invited to present his work at many national and international symposia. He also leads the Clinical Research Committee within the Department of Stem Cell Transplantation, and serves as a member of the Advisory Council of Clinical Research Leaders at the MD Anderson Cancer Center.